Back to top
more

Viatris (VTRS)

(Delayed Data from NSDQ)

$10.89 USD

10.89
7,069,885

+0.09 (0.83%)

Updated Jul 10, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

Viatris (VTRS) Q2 Earnings and Revenues Beat Estimates

Viatris (VTRS) delivered earnings and revenue surprises of 5.63% and 0.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) to Report Q2 Earnings: What's in the Offing?

Viatris' (VTRS) Q2 results are likely to be impacted by foreign exchange rates. Nevertheless, momentum in the branded business is likely to have continued.

Viatris (VTRS) Flat As Market Gains: What You Should Know

Viatris (VTRS) closed the most recent trading day at $9.85, making no change from the previous trading session.

Why Is Viatris (VTRS) Down 2.4% Since Last Earnings Report?

Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Theravance's (TBPH) Q1 Earnings and Revenues Miss Estimates

Thervance's (TBPH) first-quarter 2023 loss wider than expected. Revenues decline year over year and also miss estimates.

Viatris (VTRS) Q1 Earnings Beat, Revenues Miss Estimates

Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling its biosimilars portfolio.

Viatris (VTRS) Tops Q1 Earnings Estimates

Viatris (VTRS) delivered earnings and revenue surprises of 13.04% and 1.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) to Report Q1 Earnings: What's in the Offing?

Viatris' (VTRS) Q1 results are likely to be impacted by competitive pressure. With the Biocon deal closed, investors await its impact on first-quarter sales.

Bausch + Lomb (BLCO) Q1 Earnings Lag Estimates

Bausch + Lomb (BLCO) delivered earnings and revenue surprises of -28.57% and 3.98%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) Gains As Market Dips: What You Should Know

Viatris (VTRS) closed the most recent trading day at $9.36, moving +0.32% from the previous trading session.

Icon PLC (ICLR) Q1 Earnings and Revenues Lag Estimates

Icon PLC (ICLR) delivered earnings and revenue surprises of -2.68% and 0.35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

The Zacks Analyst Blog Highlights Humana, Viatris, agilon health and Cano Health

Humana, Viatris, agilon health and Cano Health are included in this Analyst Blog.

Viatris (VTRS) Dips More Than Broader Markets: What You Should Know

Viatris (VTRS) closed the most recent trading day at $9.18, moving -1.61% from the previous trading session.

Ocuphire (OCUP) to Report Q1 Earnings: What's in the Cards?

Occuphire (OCUP) is expected to provide updates on its proprietary ophthalmic platform for treating refractive and retinal eye disorders, on its first-quarter earnings call.

Kaibalya Pravo Dey headshot

4 Healthcare Stocks Poised to Beat Q1 Earnings Estimates

Growing patient volumes, admissions, health awareness and technological improvement in the first quarter are likely to have aided healthcare players like Humana (HUM), Viatris (VTRS), agilon health (AGL) and Cano Health (CANO).

Viatris (VTRS) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Viatris (VTRS) closed at $9.88, marking a -0.3% move from the previous day.

Why Is Viatris (VTRS) Down 16.4% Since Last Earnings Report?

Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Theravance's (TBPH) Q4 Earnings and Revenues Miss Estimates

Thervance's (TBPH) fourth-quarter loss wider than expected. Revenues decline year over year.

Viatris' (VTRS) Q4 Earnings In-Line, Revenues Miss Estimates

Viatris (VTRS) reports in-line Q4 earnings but misses on sales. The company is now looking to reshape its business after selling its biosimilars portfolio.

Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Viatris (VTRS) Matches Q4 Earnings Estimates

Viatris (VTRS) delivered earnings and revenue surprises of 0% and 2.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Teladoc (TDOC) Reports Q4 Loss, Tops Revenue Estimates

Teladoc (TDOC) delivered earnings and revenue surprises of 14.81% and 0.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for

Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.